Abstract:The present study highlights the importance of inflammatory response‐related genes in UCEC patients. UCEC patients differ in the expression of IRRGs and could be stratified into different subgroups based on this. Subtype A UCEC patients display better sensitivity to immunotherapy and chemotherapy and, thus, better prognosis. Stratification of patients into different treatment response groups facilitates the formulation of targeted therapy. Furthermore, a novel signature incorporating 12 IRRGs can accurately stratify UCEC patients into high‐ and low‐risk groups and predict the prognosis of these patients. The findings of our study have significant implications for UCEC treatment. Uterine corpus endometrial carcinoma (UCEC) is a prevalent form of cancer in women, affecting the inner lining of the uterus. Inflammation plays a crucial role in the progression and prognosis of cancer, making it important to identify inflammatory response‐related subtypes in UCEC for targeted therapy and personalized medicine. This study discovered significant variation in immune response within UCEC tumors based on molecular subtypes of inflammatory response‐related genes. Subtype A showed a more favorable prognosis and better response to immunotherapies like anti‐CTLA4 and anti‐PDCD1 therapy. Functional analysis revealed subtype‐specific differences in immune response, with subtype A exhibiting higher expression of genes related to cytokine signaling pathways, NK cell‐mediated cytotoxicity pathways and inflammatory processes. Subtype A also showed increased sensitivity to three chemotherapeutic agents. A 12‐gene inflammatory response‐related signature was found to have prognostic value for 1, 2 and 3 year survival in UCEC patients. Additionally, a validated machine learning‐based signature demonstrated significant differences in clinical traits between low‐risk and high‐risk cohorts. Elevated risk scores were associated with higher pathological grading, older age, advanced stage and immune subtype C2. Low‐risk groups had higher infiltration of immune cell types such as CD8 + T cells and activated CD4 + cells. However, the abundance of cytotoxic immune cells decreased with increasing risk scores. Finally, PCR was applied to test the different expression in P2PX4. P2RX4 knockdown inhibited the proliferation and proliferation of the endometrial carcinoma Ishikawa cell line. In conclusion, this developed signature can serve as a clinical prediction index and reveal distinct immune expression patterns. Ultimately, this study has the potential to enhance targeted therapy and personalized medicine for UCEC patients.

The inflammatory response‐related robust machine learning signature in endometrial cancer: Based on multi‐cohort studies

Identification of a 3-Cuproptosis-associated-lncrna-signature That Predicts the Prognosis of Endometrial Cancer Patients

Identification and Validation of a Seven Cuproptosis-Associated Lncrna Signature to Predict the Prognosis of Endometrial Cancer

Identification of a Novel Immune Landscape Signature for Predicting Prognosis and Response of Endometrial Carcinoma to Immunotherapy and Chemotherapy

Identification of immune-related gene signature for predicting prognosis in uterine corpus endometrial carcinoma

Endoplasmic reticulum stress related IncRNA signature predicts the prognosis and immune response evaluation of uterine corpus endometrial carcinoma

A novel chromatin regulator-related immune checkpoint related gene prognostic signature and potential candidate drugs for endometrial cancer patients

Identification of molecular subtypes premised on the characteristics of immune infiltration of endometrial cancer

Pyroptosis-related Lncrnas Are Potential Biomarkers for Predicting Prognoses and Immune Responses in Patients with UCEC

Identification of an integrated kinase-related prognostic gene signature associated with tumor immune microenvironment in human uterine corpus endometrial carcinoma

Construction and verification of an endoplasmic reticulum stress-related prognostic model for endometrial cancer based on WGCNA and machine learning algorithms

Development and Clinical Validation of Novel 8-Gene Prognostic Signature Associated With the Proportion of Regulatory T Cells by Weighted Gene Co-Expression Network Analysis in Uterine Corpus Endometrial Carcinoma

Integrated analysis of immune-related genes in endometrial carcinoma

Identification of an inflammatory response-related gene prognostic signature and immune microenvironment for cervical cancer

Integrated analysis and experiments uncover the function of disulfidptosis in predicting immunotherapy effectiveness and delineating immune landscapes in uterine corpus endometrial carcinoma

Integrated bioinformatics analysis and experimental validation reveals fatty acid metabolism-related prognostic signature and immune responses for uterine corpus endometrial carcinoma

A stemness-based signature with inspiring indications in discriminating the prognosis, immune response, and somatic mutation of endometrial cancer patients revealed by machine learning

Development of an Oxidative Phosphorylation-Related and Immune Microenvironment Prognostic Signature in Uterine Corpus Endometrial Carcinoma

Identification of an immune checkpoint gene signature that accurately predicts prognosis and immunotherapy response in endometrial carcinoma

Integrated machine learning identifies a cellular senescence-related prognostic model to improve outcomes in uterine corpus endometrial carcinoma

Risk prediction model of uterine corpus endometrial carcinoma based on immune-related genes